When can dapagliflozin be initiated in a patient with acute kidney injury and ischemic heart disease, and what eGFR threshold is required?

Dapagliflozin Initiation in Acute Kidney Injury and Ischemic Heart Disease

Do not initiate dapagliflozin during active acute kidney injury (AKI); wait until kidney function stabilizes and eGFR is ≥25 mL/min/1.73 m² for cardiovascular or renal protection indications, or ≥45 mL/min/1.73 m² if the sole goal is glycemic control. 1

eGFR Thresholds for Initiation

For Cardiovascular and Renal Protection (Heart Failure, CKD)

• Dapagliflozin may be initiated at eGFR ≥25 mL/min/1.73 m² when used to reduce cardiovascular death, heart failure hospitalization, or chronic kidney disease progression. 1
• The FDA label explicitly states: "Initiation with dapagliflozin is not recommended in patients with an eGFR less than 25 mL/min/1.73 m²." 1
• The 2022 ADA/KDIGO consensus confirms that SGLT2 inhibitors with proven kidney or cardiovascular benefit can be initiated at eGFR ≥20 mL/min/1.73 m², though dapagliflozin's specific FDA threshold is 25 mL/min/1.73 m². 2

For Glycemic Control Alone

• Dapagliflozin should not be initiated for glycemic control when eGFR <45 mL/min/1.73 m², as it is likely ineffective due to its mechanism requiring adequate glomerular filtration. 1
• This restriction applies specifically to patients without established cardiovascular disease or cardiovascular risk factors. 1

Management During Acute Kidney Injury

Withholding During AKI

• Temporarily discontinue dapagliflozin during active AKI until volume status is corrected and kidney function stabilizes. 2, 1
• The FDA label mandates assessing volume status before initiation and correcting volume depletion first. 1
• SGLT2 inhibitors cause osmotic diuresis, which can exacerbate hypovolemia and worsen AKI in the acute setting. 2

When to Resume or Initiate After AKI Resolution

• Reassess eGFR after AKI resolves; if stable at ≥25 mL/min/1.73 m², dapagliflozin may be initiated for cardiovascular or renal protection. 1
• Ensure the patient is euvolemic, hemodynamically stable, and not requiring intravenous diuretics or vasopressors. 3
• The DAPA-CKD trial demonstrated that dapagliflozin actually reduces the risk of subsequent AKI episodes once chronic therapy is established, but this protective effect requires stable baseline kidney function. 4, 5

Initiation in Ischemic Heart Disease

Heart Failure Context

• For patients with ischemic heart disease and heart failure (either HFrEF or HFpEF), initiate dapagliflozin 10 mg once daily when eGFR ≥25 mL/min/1.73 m². 1, 6
• In-hospital initiation during acute heart failure is supported by emerging evidence, but patients must be stabilized first—defined as no increase in IV loop diuretics for 6 hours and no IV inotropes for 24 hours. 3, 7
• The EMPULSE and DAPA-ACT HF-TIMI 68 trials enrolled patients on hospital days 2–7 after stabilization, demonstrating safety and efficacy of early initiation. 3

Without Heart Failure

• For ischemic heart disease without heart failure, dapagliflozin is indicated if the patient has type 2 diabetes with established cardiovascular disease or multiple cardiovascular risk factors and eGFR ≥25 mL/min/1.73 m² (or ≥45 mL/min/1.73 m² if glycemic control is the primary goal). 1

Safety Considerations and Monitoring

Volume Status and Hypotension

• Assess for volume depletion before initiating dapagliflozin, particularly in patients ≥65 years, those on loop diuretics, or with recent AKI. 1
• Consider reducing loop diuretic dose by 25–50% if the patient appears euvolemic or volume-depleted to mitigate hypotension risk. 2
• Monitor blood pressure and orthostatic vital signs within 1–2 weeks of initiation. 2

Acute eGFR Dip

• An acute, reversible eGFR decline of 3–5 mL/min/1.73 m² is expected within 2 weeks of starting dapagliflozin due to hemodynamic effects on intraglomerular pressure. 5
• This acute dip does not predict worse long-term kidney outcomes; in fact, patients experiencing a >10% acute eGFR reduction had slower long-term eGFR decline (-1.58 vs. -2.44 mL/min/1.73 m² per year). 5
• Do not discontinue dapagliflozin for an acute eGFR dip unless the patient develops symptomatic hypotension, volume depletion, or AKI from another cause. 2, 5

Ketoacidosis Risk

• Euglycemic diabetic ketoacidosis can occur, especially during acute illness, surgery, or prolonged fasting. 1
• Withhold dapagliflozin at least 3 days before major surgery or procedures with prolonged fasting. 1
• Educate patients to stop dapagliflozin during acute febrile illness, vomiting, or reduced oral intake and to check urine or blood ketones if feeling unwell. 2, 1

Genital Mycotic Infections

• Genital mycotic infections occur in approximately 6% of patients on SGLT2 inhibitors, with higher risk in women. 2
• Daily hygiene measures reduce risk; most infections are easily treated, but rare cases of Fournier gangrene have been reported. 2

Continuation Below Initiation Threshold

If eGFR Falls After Starting Therapy

• Continue dapagliflozin even if eGFR falls below 25 mL/min/1.73 m² after initiation, unless the patient is not tolerating treatment or requires dialysis. 1, 6
• The DAPA-CKD and DELIVER trials allowed continuation below the initiation threshold, demonstrating sustained cardiovascular and renal benefits. 1, 6, 4
• Patients with eGFR deterioration to <25 mL/min/1.73 m² who continued dapagliflozin had a 47% lower risk of the primary composite outcome (HR 0.53,95% CI 0.33–0.83) compared with placebo, with no excess safety events. 6

Common Pitfalls to Avoid

• Do not initiate dapagliflozin during active AKI or volume depletion; stabilize the patient first. 2, 1
• Do not discontinue dapagliflozin for an isolated acute eGFR dip of <10% within the first 2–4 weeks unless accompanied by symptoms or other complications. 5
• Do not confuse the eGFR threshold for glycemic control (≥45 mL/min/1.73 m²) with the threshold for cardiovascular/renal protection (≥25 mL/min/1.73 m²); the indication determines the threshold. 1
• Do not forget to adjust insulin or sulfonylurea doses when initiating dapagliflozin in patients with diabetes to reduce hypoglycemia risk. 2
• Do not initiate in patients with polycystic kidney disease or those requiring immunosuppression for kidney disease, as dapagliflozin is not expected to be effective in these populations. 1